277 related articles for article (PubMed ID: 19962744)
21. Activation of Human Basophils by A549 Lung Epithelial Cells Reveals a Novel IgE-Dependent Response Independent of Allergen.
Schroeder JT; Bieneman AP
J Immunol; 2017 Aug; 199(3):855-865. PubMed ID: 28652400
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
24. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders.
Foroughi S; Foster B; Kim N; Bernardino LB; Scott LM; Hamilton RG; Metcalfe DD; Mannon PJ; Prussin C
J Allergy Clin Immunol; 2007 Sep; 120(3):594-601. PubMed ID: 17765756
[TBL] [Abstract][Full Text] [Related]
25. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization.
Schroeder JT; Bieneman AP; Chichester KL; Hamilton RG; Xiao H; Saini SS; Liu MC
J Allergy Clin Immunol; 2010 Apr; 125(4):896-901.e6. PubMed ID: 20132969
[TBL] [Abstract][Full Text] [Related]
26. Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.
Gomez G
Front Immunol; 2019; 10():175. PubMed ID: 30792720
[TBL] [Abstract][Full Text] [Related]
27. Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
Shamji MH; Singh I; Layhadi JA; Ito C; Karamani A; Kouser L; Sharif H; Tang J; Handijiev S; Parkin RV; Durham SR; Kostic A; Orengo JM; DeVeaux M; Kamal M; Stahl N; Yancopoulos GD; Wang CQ; Radin AR
Am J Respir Crit Care Med; 2021 Jul; 204(1):23-33. PubMed ID: 33651675
[No Abstract] [Full Text] [Related]
28. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge.
Corren J; Wood RA; Patel D; Zhu J; Yegin A; Dhillon G; Fish JE
J Allergy Clin Immunol; 2011 Feb; 127(2):398-405. PubMed ID: 21281870
[TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
30. The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment.
Johansson SGO; Nopp A; Öman H; Ankerst J; Cardell LO; Grönneberg R; Matsols H; Rudblad S; Strand V; Stålenheim G
Allergy; 2009 Oct; 64(10):1472-1477. PubMed ID: 19393000
[TBL] [Abstract][Full Text] [Related]
31. Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.
Eggel A; Baravalle G; Hobi G; Kim B; Buschor P; Forrer P; Shin JS; Vogel M; Stadler BM; Dahinden CA; Jardetzky TS
J Allergy Clin Immunol; 2014 Jun; 133(6):1709-19.e8. PubMed ID: 24642143
[TBL] [Abstract][Full Text] [Related]
32. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
[TBL] [Abstract][Full Text] [Related]
33. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
[TBL] [Abstract][Full Text] [Related]
34. Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.
Deza G; March-Rodríguez A; Sánchez S; Ribas-Llauradó C; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
J Allergy Clin Immunol Pract; 2019; 7(5):1619-1626.e1. PubMed ID: 30685572
[TBL] [Abstract][Full Text] [Related]
35. Comparable actions of omalizumab on mast cells and basophils.
Serrano-Candelas E; Martinez-Aranguren R; Valero A; Bartra J; Gastaminza G; Goikoetxea MJ; Martín M; Ferrer M
Clin Exp Allergy; 2016 Jan; 46(1):92-102. PubMed ID: 26509363
[TBL] [Abstract][Full Text] [Related]
36. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.
Ong YE; Menzies-Gow A; Barkans J; Benyahia F; Ou TT; Ying S; Kay AB
J Allergy Clin Immunol; 2005 Sep; 116(3):558-64. PubMed ID: 16159624
[TBL] [Abstract][Full Text] [Related]
37. Inhibiting phosphatase SHIP-1 enhances suboptimal IgE-mediated activation of human blood basophils but inhibits IgE-mediated activation of cultured human mast cells.
Rasmussen P; Spillner E; Hoffmann HJ
Immunol Lett; 2019 Jun; 210():40-46. PubMed ID: 31004680
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.
Frischmeyer-Guerrerio PA; Masilamani M; Gu W; Brittain E; Wood R; Kim J; Nadeau K; Jarvinen KM; Grishin A; Lindblad R; Sampson HA
J Allergy Clin Immunol; 2017 Oct; 140(4):1043-1053.e8. PubMed ID: 28414061
[TBL] [Abstract][Full Text] [Related]
39. Omalizumab inhibits allergen challenge-induced nasal response.
Hanf G; Noga O; O'Connor A; Kunkel G
Eur Respir J; 2004 Mar; 23(3):414-8. PubMed ID: 15065831
[TBL] [Abstract][Full Text] [Related]
40. Sequential engagement of FcεRI on Mast Cells and Basophil Histamine H(4) Receptor and FcεRI in Allergic Rhinitis.
Shiraishi Y; Jia Y; Domenico J; Joetham A; Karasuyama H; Takeda K; Gelfand EW
J Immunol; 2013 Jan; 190(2):539-48. PubMed ID: 23241885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
